$SVA

Sinovac Biotech Ltd. (SVA) reported a net loss of $96.6 million for the first half of 2025, a significant swing from a net income of $59.0 million in the prior year, primarily due to reduced investment income and impairment charges related to a rabies vaccine subsidiary. The company also announced that its previously issued unaudited financial results for the first half of 2024 should no longer be relied upon and have been restated to correct errors in areas such as legal matters, revenue recognition, and investment classifications. Despite these financial challenges, Sinovac holds a strong cash position of $4.2 billion as of June 30, 2025, which supported a special cash dividend of $55.00 per share, totaling $4.0 billion.